Insulin Market Size Worth $23.20 Billion by 2030 - Grand View Research, Inc.

News provided by

Jul 20, 2022, 09:30 ET

SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- The global insulin market is expected to reach USD 23.20 billion by 2030, expanding at a CAGR of 1.5% during the forecast period, according to a new report by Grand View Research, Inc. It is an oligopolistic space dominated by companies such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. The increasing incidence of diabetes and formulation advancements in insulin delivery are the primary factors driving growth. However, the presence of biosimilars and drugs such as GLP-1 RAs for the treatment of type 2 diabetes can slow down market growth to a certain extent.

Key Industry Insights & Findings from the report:

The long-acting insulin segment contributed a significant revenue share of 56.53% in 2021. Factors such as patent protection and high demand due to long-term effects are expected to drive the segment.
Type 1 diabetes mellitus is the largest segment by application in 2021 due to the high insulin dependency of these patients.
Insulin analog segment dominated in 2021. It is due to the higher efficacy of insulin and minimal adverse effects, such as hypoglycemic attacks and lower weight gain, as compared to conventional therapy.
The retail pharmacy segment dominated the distribution channel in 2021 due to the presence of retail pharmacy chains and tie-ups of these chains with hospitals.
North America dominated the market in terms of revenue in 2021, mainly due to the dominance of branded products and the increasing prevalence of diabetes in the region.

Read 150-page market research report, "Insulin Market Size, Share & Trends Analysis By Product Type (Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar), By Application, By Type (Type 1, Type 2), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Insulin Market Growth & Trends

Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The prevalence of the disease is growing rapidly in low- and middle-income countries; three in four adults live with diabetes in these countries. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. In addition, the increase in geriatric and obese populations is another factor driving growth. The overweight population is at risk of developing type 2 diabetes mellitus. According to WHO, in 2020, 1.9 billion adults were found to be overweight, accounting for 39% of the population within that age group.

Formulation advancements in insulin delivery systems are being developed, the release of which is likely to propel the market over the forecast period. In December 2019, Tandem Diabetes Care's Control-IQ, an interoperable device, received FDA authorization for marketing in the U.S. It is an automated insulin dosing algorithm that can be used with other interoperable devices.

The top three manufacturing companies, Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, hold a monopoly. These companies hold more than 90% of the market share. Owing to the oligopolistic nature of the market and patent protection, the cost of insulin is high. Hence, the high cost of products could impede industry growth.

The COVID-19 pandemic caused a detrimental impact on the industry. Individuals with chronic illnesses, such as diabetes, have experienced substantial disruptions in emergency and routine medical care. According to an NCBI article, out of ~30 million diabetic patients in America, about 7.5 million are dependent on insulin. Insulin rationing or hoarding has already been a rampant issue, which increased further amid the pandemic due to supply concerns. However, in several countries, the effect of COVID-19 declined to post the third quarter of 2020, which helped the market regain traction.

Insulin Market Segmentation

Grand View Research has segmented the global Insulin market based on product type, application, type, distribution channel, and regions:

Insulin Market - Product Type Outlook (Revenue, USD Million, 2018 - 2030)

Rapid-Acting Insulin
Long-Acting Insulin
Combination Insulin
Biosimilar
Others

Insulin Market - Type Outlook (Revenue, USD Million, 2018 - 2030)

Human Insulin
Insulin Analog

Insulin Market - Application Outlook (Revenue, USD Million, 2018 - 2030)

Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Insulin Market - Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals
Retail Pharmacies
Others

Insulin Market - Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.
Canada

Europe

Germany
U.K.
France
Italy
Spain

Asia Pacific

Japan
China
India
Australia
South Korea

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

South Africa
Saudi Arabia
UAE

List of Key Players of Insulin Market

Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Biocon Ltd
Wockhardt
Boehringer Ingelheim International GmbH
Julphar
United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co. Ltd.

Check out more related studies published by Grand View Research:

Insulin Pump Market - The global insulin pump market size is expected to reach USD 8.3 billion, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.7% from 2021 to 2028. The key factors driving the growth of the market are the technological advancements and the adoption of pumps over traditional methods.
Insulin Delivery Devices Market - The global insulin delivery devices market size is expected to reach USD 27.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.4% from 2022 to 2030. Obesity, sedentary lifestyles, and unhealthy food habits, primarily in the young population, lead to the occurrence of diabetes.
Smart Insulin Pens & Pumps Market - The global smart insulin pens and pumps market size is expected to reach USD 6.3 billion by 2026, registering around 10.0% CAGR over the forecast period according to a new report by Grand View Research, Inc. Major market drivers include continuous technological advancements in the field of diabetes care along with growing adoption of advanced diabetes management methods.

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Astra ESG Solutions
Follow Us: LinkedIn | Twitter